Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single-arm study.
biomarker
cryobiopsy
cryoprobe
immunohistochemistry
lung cancer
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
22
03
2020
revised:
09
05
2020
accepted:
13
05
2020
pubmed:
20
5
2020
medline:
11
8
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
Cryoprobe is a novel transbronchial biopsy (TBB) tool that yields larger tissue samples than forceps. Pathological diagnosis and biomarker analysis, such as genetic alterations and programmed death-ligand 1 (PD-L1) expression, are paramount for precision medicine against lung cancer. We evaluated the safety and usefulness of cryoprobe TBB for lung cancer diagnosis and biomarker analysis. In this single-center, prospective single-arm study, patients suspected of having or diagnosed with primary lung cancer underwent cryoprobe TBB using flexible bronchoscopy after conventional forceps TBB from the same lesion. Cryoprobe TBB was performed in 121 patients. The incidence rate of severe bleeding and serious adverse events (4% [90% confidence interval: 2%-9%]) was significantly lower than the expected rate (20% with 30% threshold, P < 0.01). Combining both central and peripheral lesions, the diagnostic yield rate of cryoprobe samples was 76% and that of forceps samples was 84%. Compared with forceps TBB samples, cryoprobe TBB samples were larger (cryoprobe 15 mm
Identifiants
pubmed: 32426898
doi: 10.1111/cas.14489
pmc: PMC7385344
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2488-2498Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP16ck0106041
Organisme : Japan Agency for Medical Research and Development
ID : JP18ck0106411
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Respir Care. 2016 May;61(5):700-12
pubmed: 26932382
Cancer Sci. 2020 Jul;111(7):2488-2498
pubmed: 32426898
J Bronchology Interv Pulmonol. 2016 Apr;23(2):174-6
pubmed: 26496093
Jpn J Clin Oncol. 2019 Jun 1;49(6):559-566
pubmed: 30882147
Eur Respir J. 2015 Aug;46(2):521-31
pubmed: 25976686
Respir Med. 2006 Oct;100(10):1753-9
pubmed: 16584880
J Clin Med. 2018 Jun 29;7(7):
pubmed: 29966246
Lung. 2009 Aug;187(4):253-9
pubmed: 19548030
Front Oncol. 2014 Aug 11;4:204
pubmed: 25157335
Clin Respir J. 2016 Sep;10(5):589-95
pubmed: 25620578
Respiration. 2019;98(2):133-141
pubmed: 31018210
Eur Respir J. 2012 Mar;39(3):685-90
pubmed: 21852332
Eur Respir J. 2014 Oct;44(4):1011-22
pubmed: 25102961
Respirology. 2016 Jul;21(5):834-41
pubmed: 26991519
Respir Investig. 2019 Mar;57(2):150-156
pubmed: 30470645
Adv Respir Med. 2017;85(6):301-306
pubmed: 29288478
Respiration. 2018;95(3):188-200
pubmed: 29316560
Respiration. 2017;94(3):285-292
pubmed: 28743122
Arch Bronconeumol. 2015 Jun;51(6):261-7
pubmed: 25454902
Respiration. 2006;73(4):399-409
pubmed: 16775411
Chest. 2013 Mar;143(3):621-626
pubmed: 23328889
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):576-81
pubmed: 15767332
J Thorac Cardiovasc Surg. 2010 Aug;140(2):417-21
pubmed: 20226474
Immunotherapy. 2017 May;9(6):499-506
pubmed: 28472902
Cancers (Basel). 2019 Mar 22;11(3):
pubmed: 30909479
Respir Investig. 2019 May;57(3):245-251
pubmed: 30745273
Chest. 2013 May;143(5 Suppl):e142S-e165S
pubmed: 23649436